THEOFIBRATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C19H21ClN4O5
Molecular Weight	420.847
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN1C2=C(N(CCOC(=O)C(C)(C)OC3=CC=C(Cl)C=C3)C=N2)C(=O)N(C)C1=O

InChI

InChIKey=KYAKGJDISSNVPZ-UHFFFAOYSA-N

InChI=1S/C19H21ClN4O5/c1-19(2,29-13-7-5-12(20)6-8-13)17(26)28-10-9-24-11-21-15-14(24)16(25)23(4)18(27)22(15)3/h5-8,11H,9-10H2,1-4H3

HIDE SMILES / InChI

Molecular Formula	C19H21ClN4O5
Molecular Weight	420.847
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7728839
Curator's Comment: description was created based on several sources, including https://www.drugs.com/international/theofibrate.html | https://www.ncbi.nlm.nih.gov/pubmed/7045566 | https://www.drugs.com/international/etofylline-clofibrate.html | https://www.ncbi.nlm.nih.gov/pubmed/7045566

Theofibrate (Etofylline clofibrate, trade name Duolip) is the clofibric acid ester of theophylline, used for the treatment of hyperlipoproteinaemia with elevated triglycerides and cholesterol. The low dose of Etophylline clofibrate (750mg) has a similar lipid-lowering effect as pure clofibrate (1500mg), probably due to a synergistic hypolipidemic effect with theophylline, which has no lipid-lowering effect per se. Secondly, etophylline clofibrate substantially decreases platelet aggregability and plasma viscosity, properties which may be desirable in the prevention of coronary heart disease (CHD). Finally, etophylline clofibrate is clearly a less potent inducer of peroxisomal proliferation in the rat liver than clofibrate, bezafibrate or fenofibrate. Theofibrate increases lipoprotein lipase activity to promote the conversion of Very low-density lipoprotein (VLDL) to Low-density lipoprotein (LDL), and hence reduce the level of VLDL.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
very-low-density lipoprotein particle remodeling 1 Target ID: GO:0034372 Sources: https://www.ncbi.nlm.nih.gov/pubmed/4004984	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Familial combined hyperlipidemia 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7762188	Primary		Approved 8583	Duolip forte Approved Use Unknown

Doses

Dose	Population	Adverse events
750 mg 3 times / day multiple, oral Highest studied dose Dose: 750 mg, 3 times / day Route: oral Route: multiple Dose: 750 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7194059/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7194059/	Sources: https://pubmed.ncbi.nlm.nih.gov/7194059/
750 mg 3 times / day multiple, oral Highest studied dose Dose: 750 mg, 3 times / day Route: oral Route: multiple Dose: 750 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7194062/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7194062/	Sources: https://pubmed.ncbi.nlm.nih.gov/7194062/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	P-gp 2052 CYP19A1 26

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 2633	inducer 1966 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/41109#section=Biological-Test-Results Page: 102.0	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/41109#section=Biological-Test-Results Page: 1 \| 72 \| 103	no [IC50 18.3564 uM]
CYP19A1 26	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/41109#section=Biological-Test-Results Page: 99.0	yes [Activation 18.3564 uM]

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/41109#section=Biological-Test-Results Page: 50.0

PubMed

Title	Date	PubMed
Effect of etofylline clofibrate on experimental thrombus formation and prostacyclin activation.	1986-09	3539125

Patents

Sample Use Guides

In Vivo Use Guide

500 - 750 mg once daily for 12-16 weeks

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:54:52 GMT 2025` Edited by `admin` on `Mon Mar 31 17:54:52 GMT 2025`
Record UNII	14UH1JQP6L
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

THEOFIBRATE

Official Name

English

ETOFYLLINE CLOFIBRATE

Preferred Name

English

ETOFYLLINE CLOFIBRATE [MART.]

Common Name

English

ML-1024

Code

English

CLOFIBRATE ETOFYLLINE

Common Name

English

etofylline clofibrate [INN]

Common Name

English

NSC-234348

Code

English

DUOLIP

Brand Name

English

PROPANOIC ACID, 2-(4-CHLOROPHENOXY)-2-METHYL-, 2-(1,2,3,6-TETRAHYDRO-1,3-DIMETHYL-2,6-DIOXO-7H-PURIN-7-YL)ETHYL ESTER

Common Name

English

Etofylline clofibrate [WHO-DD]

Common Name

English

2-(P-CHLOROPHENOXY)-2-METHYLPROPIONIC ACID, ESTER WITH 7-(2-HYDROXYETHYL)THEOPHYLLINE

Common Name

English

THEOFIBRATE [USAN]

Common Name

English

THEOFIBRATE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C98150